scPharmaceuticals Inc. (NASDAQ:SCPH – Free Report) – Equities researchers at HC Wainwright decreased their FY2023 EPS estimates for scPharmaceuticals in a research report issued to clients and investors on Thursday, November 9th. HC Wainwright analyst D. Tsao now expects that the company will earn ($1.39) per share for the year, down from their previous estimate of ($1.31). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for scPharmaceuticals’ Q4 2023 earnings at ($0.32) EPS, Q1 2024 earnings at ($0.32) EPS, Q2 2024 earnings at ($0.28) EPS, Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($1.07) EPS and FY2025 earnings at ($0.05) EPS.
Separately, Craig Hallum started coverage on shares of scPharmaceuticals in a research note on Thursday, September 7th. They issued a “buy” rating and a $20.00 target price for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $20.17.
scPharmaceuticals Stock Up 4.5 %
SCPH stock opened at $4.91 on Monday. The company has a market cap of $176.07 million, a price-to-earnings ratio of -3.58 and a beta of 0.13. scPharmaceuticals has a twelve month low of $4.63 and a twelve month high of $12.75. The business has a 50 day moving average price of $6.33 and a two-hundred day moving average price of $8.38. The company has a quick ratio of 16.24, a current ratio of 9.53 and a debt-to-equity ratio of 0.78.
scPharmaceuticals (NASDAQ:SCPH – Get Free Report) last released its earnings results on Thursday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. The company had revenue of $1.64 million during the quarter, compared to analyst estimates of $1.55 million.
Institutional Investors Weigh In On scPharmaceuticals
A number of large investors have recently added to or reduced their stakes in SCPH. Virtu Financial LLC bought a new stake in shares of scPharmaceuticals during the second quarter worth approximately $53,000. Cubist Systematic Strategies LLC acquired a new position in scPharmaceuticals in the 3rd quarter valued at $75,000. BNP Paribas Arbitrage SNC grew its holdings in scPharmaceuticals by 348.5% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 7,633 shares of the company’s stock valued at $78,000 after buying an additional 5,931 shares in the last quarter. State Street Corp increased its position in scPharmaceuticals by 15.0% during the 2nd quarter. State Street Corp now owns 17,360 shares of the company’s stock worth $84,000 after buying an additional 2,260 shares during the period. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of scPharmaceuticals during the third quarter worth $92,000. Institutional investors own 79.60% of the company’s stock.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.
- Five stocks we like better than scPharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 11/6 – 11/10
- Investing in Blue-Chip Stocks
- Data giants MongoDB and Snowflake just got upgraded
- How to Invest in Toy Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.